Small Animal Imaging Core

小动物成像核心摘要 随着临床前成像越来越多地用于药物发现和开发， 小动物成像（SAI）核心已成为建议中不可或缺的组成部分 CCNE赠款，目标是提供尖端的成像技术和专业知识， 促进每个项目的纳米颗粒技术开发。SAI核心已经很长时间了 自CCNE第一阶段以来，我一直参与CCNE项目，并做出了重大贡献 在纳米技术的发展，提供全面的支持，在体内光学 成像、microCT成像、MR成像、PET/CT、SPECT/CT、超声成像，以及 在过去的两个CCNE阶段中，对十个项目进行了多模态成像技术的组合。对 另一方面，成像核心在过去十年中有了显著的扩展。我们 成像设备从2004年的一个MRI和一个光学系统增加到目前的 11种成像系统，几乎涵盖了所有的动物成像模式。近期 搬迁到新大楼后，设施面积扩大到40，000多平方英尺， 升级的实验室空间新的回旋加速器和放射化学设施进一步增强了 分子成像能力，能够按需在附近生产成像探针， 成像探针的开发。放射化学和放射性药物学的教师招聘 增加了具有放射合成和转化成像研究专业知识的成像核心。 作为补给核心设施，成像核心也取得了相当大的成就， 加强日程安排、登记、动物支持、议定书等基础设施 开发、系统维护和计费。 利用这些令人印象深刻的资源和能力，最高审计机关核心旨在提供 先进的成像技术，以促进拟议的项目。有两个具体目标， 建议：1）优化生物分布研究的光学和PET成像方法; 2）开发 多模态成像方法来评估癌症治疗效果。具体来说，光学 成像和PET/CT成像将用于表征开发的纳米颗粒， 纳米药物在四个项目中的PK和生物分布。此外，多模式 将使用成像，包括光学、超声、microCT和PET/CT成像， 项目1-4的治疗效果。总的来说，我们认为增强的成像能力和 SAI核心的基础设施将大大有利于纳米药物的开发，并促进 所提出的项目的成功。

Small Animal Imaging Core Abstract As the preclinical imaging has been increasingly used in drug discovery and development, the Small Animal Imaging (SAI) core has become an indispensable component in the proposed CCNE grant, with the goal of providing cutting edge imaging techniques and expertise to facilitate nanoparticle technology development in each project. The SAI core has been long involved in the CCNE projects since the CCNE phase I, and has made substantial contributions in the nanotechnology development by providing comprehensive support on in vivo optical imaging, microCT imaging, MR imaging, PET/CT, SPECT/CT, ultrasound imaging, and the combined multimodality imaging technique on ten projects in the past two CCNE phases. On the other hand, the imaging core has had significant expansion in the past ten years. Our imaging equipment has increased from one MRI and one optical system in 2004 to current eleven imaging systems covering almost all the animal imaging modalities. The recent relocation to the new building has expanded the facility space to more than 40,000 sq ft with upgraded lab space. The new cyclotron and radiochemistry facility further enhanced the molecular imaging capability, enabling on-demand imaging probes produced nearby and novel imaging probes development. Faculty recruitment on radiochemistry and radiopharmacy has added the imaging core with the expertise on radiosynthesis and translational imaging studies. Operated as a recharge core facility, the imaging core has also made considerable enhancement in the infrastructures on scheduling, registration, animal support, protocol development, system maintenance, and billing. Leveraging on these impressive resources and capacities the SAI core aims to provide advanced imaging technology to facilitate the proposed projects. Two specific aims have been proposed: 1) Optimize optical and PET imaging methods for biodistribution studies; 2) Develop multimodality imaging approach to evaluate cancer treatment efficacy. Specifically, optical imaging and PET/CT imaging will be used to characterize developed nanoparticles or nanodrugs in terms of PK and biodistribution in the four projects. In addition, multimodality imaging, including optical, ultrasound, microCT, and PET/CT imaging will be used to evaluate treatment efficacy in project 1-4. Overall, we believe that the enhanced imaging capability and infrastructure in the SAI core will greatly benefit the nanodrug development, and facilitate the success of the proposed projects.